Nick Zaller1, Portia Thurmond, Josiah D Rich. 1. Department of Medicine, Division of Infectious Diseases, Miriam Hospital/Brown Medical School, Brown University, Center for Prisoner Health and Human Rights, Providence, RI 02906, USA. nzaller@lifespan.org
Abstract
OBJECTIVE: Correctional facilities provide a critical opportunity to treat and manage human immunodeficiency virus (HIV) and HIV-related complications among inmates. Inmates bear a higher HIV burden than the general population, and many have never received HIV care prior to incarceration. The standard of care in the community and in corrections for the treatment of HIV is highly active antiretroviral therapy (HAART). This study evaluated U.S. correctional expenditures for antiretrovirals (ARVs) and compared them to the estimated need for ARVs among HIV-infected prisoners in the U.S. to treat this population successfully. METHODS: The total number of HIV-infected prisoners in the United States was estimated using Bureau of Justice Statistics data. The National Sales Perspectives Audit, Combined Retail and Nonretail, July 1999 to December 2004 was used to estimate correctional ARV expenditures in 2004. Both measures were used to calculate treatment costs for ARV therapy. RESULTS: The analysis demonstrates that, in 2004, total ARV sales represented only 29% of the total necessary to treat all HAART eligible inmates with known HIV infection. CONCLUSION: There is a substantial unmet need for ARVs in correctional health care. Although many barriers exist to treating all eligible HIV-infected prisoners, treatment reduces costs associated with HIV-related complications and may encourage linkage to HIV care in the community. Treatment of all eligible HIV-infected inmates should be a public health priority.
OBJECTIVE: Correctional facilities provide a critical opportunity to treat and manage human immunodeficiency virus (HIV) and HIV-related complications among inmates. Inmates bear a higher HIV burden than the general population, and many have never received HIV care prior to incarceration. The standard of care in the community and in corrections for the treatment of HIV is highly active antiretroviral therapy (HAART). This study evaluated U.S. correctional expenditures for antiretrovirals (ARVs) and compared them to the estimated need for ARVs among HIV-infected prisoners in the U.S. to treat this population successfully. METHODS: The total number of HIV-infected prisoners in the United States was estimated using Bureau of Justice Statistics data. The National Sales Perspectives Audit, Combined Retail and Nonretail, July 1999 to December 2004 was used to estimate correctional ARV expenditures in 2004. Both measures were used to calculate treatment costs for ARV therapy. RESULTS: The analysis demonstrates that, in 2004, total ARV sales represented only 29% of the total necessary to treat all HAART eligible inmates with known HIV infection. CONCLUSION: There is a substantial unmet need for ARVs in correctional health care. Although many barriers exist to treating all eligible HIV-infected prisoners, treatment reduces costs associated with HIV-related complications and may encourage linkage to HIV care in the community. Treatment of all eligible HIV-infected inmates should be a public health priority.
Authors: Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: K A Freedberg; E Losina; M C Weinstein; A D Paltiel; C J Cohen; G R Seage; D E Craven; H Zhang; A D Kimmel; S J Goldie Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Anne Spaulding; Becky Stephenson; Grace Macalino; William Ruby; Jennifer G Clarke; Timothy P Flanigan Journal: Clin Infect Dis Date: 2002-07-03 Impact factor: 9.079
Authors: K R Arriola; R L Braithwaite; S Kennedy; T Hammett; M Tinsley; P Wood; C Arboleda Journal: Public Health Rep Date: 2001 Nov-Dec Impact factor: 2.792
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Steven Belenko; Richard Dembo; Michael Copenhaver; Matthew Hiller; Holly Swan; Carmen Albizu Garcia; Daniel O'Connell; Carrie Oser; Frank Pearson; Jennifer Pankow Journal: AIDS Behav Date: 2016-01
Authors: Melanie A Thompson; Michael J Mugavero; K Rivet Amico; Victoria A Cargill; Larry W Chang; Robert Gross; Catherine Orrell; Frederick L Altice; David R Bangsberg; John G Bartlett; Curt G Beckwith; Nadia Dowshen; Christopher M Gordon; Tim Horn; Princy Kumar; James D Scott; Michael J Stirratt; Robert H Remien; Jane M Simoni; Jean B Nachega Journal: Ann Intern Med Date: 2012-03-05 Impact factor: 25.391
Authors: Liza Solomon; Brian T Montague; Curt G Beckwith; Jacques Baillargeon; Michael Costa; Dora Dumont; Irene Kuo; Ann Kurth; Josiah D Rich Journal: Health Aff (Millwood) Date: 2014-03 Impact factor: 6.301